Rybelsus (Oral Semaglutide 14 mg, Diabetes)

Rybelsus (Oral Semaglutide 14 mg) stands alone as the only oral GLP-1 approved for both glycemic control and cardiovascular risk reduction in type 2 diabetes, a dual indication that expands its therapeutic reach since its September 2019 debut as the first oral GLP-1. By leveraging Novo Nordisk's SNAC absorption enhancer, it overcomes gastric degradation to deliver systemic absorption, and the SOUL trial (n=9,650) confirmed a 14% relative reduction in major adverse cardiovascular events versus placebo over 4 years, earning FDA approval for cardiovascular risk reduction in October 2025. At the 14 mg dose, PIONEER trials showed approximately 4-5 kg weight loss, which underperforms #1 Wegovy (semaglutide) by nearly 60%. Rybelsus requires strict fasting: an empty stomach, no more than 120 mL of water, and 30 minutes without food or medications. With a monthly list price from $900 to $1,000, it is more affordable than weight-loss-only GLP-1s like #2 Saxenda's $1,349 list price. For T2D patients with established cardiovascular disease, Rybelsus remains the definitive oral option, even as oral Wegovy (25 mg) enters the market.